论文部分内容阅读
目的探讨醒脑静辅助卡马西平治疗脑卒中后继发性癫痫的临床疗效及安全性。方法选取2014年2月—2016年2月北京市仁和医院收治的脑卒中后继发性癫痫患者60例,根据治疗药物不同分为对照组与观察组,各30例。两组患者均给予常规治疗,对照组在此基础上给予卡马西平口服治疗,观察组在对照组基础上加用醒脑静治疗。比较两组患者临床疗效、治疗前后累及导联数与痫样放电情况、SF-36评价量表评分及不良反应发生情况。结果观察组患者总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者累及导联数与痫样放电比较,差异无统计学意义(P>0.05),治疗后观察组患者累及导联数与痫样放电少于对照组,差异有统计学意义(P<0.05)。观察组患者生理功能、总体健康、精神健康、社会功能、心理职能、活力、躯体与心理相关生活质量、躯体疼痛及情感职能评分及总分高于对照组,差异有统计学意义(P<0.05)。观察组患者不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论醒脑静辅助卡马西平治疗脑卒中后继发性癫痫的临床疗效优良,且安全性高。
Objective To investigate the clinical efficacy and safety of xingnaojing-assisted carbamazepine in the treatment of secondary epilepsy after stroke. Methods Sixty patients with secondary epilepsy after stroke were enrolled in Renhe Hospital of Beijing from February 2014 to February 2016. The patients were divided into control group and observation group with 30 cases in each group. Both groups were given routine treatment, the control group on the basis of oral carbamazepine treatment, the observation group in the control group based on the use of Xingnaojing treatment. The clinical curative effect, the number of leads involved in epileptiform discharge, the score of SF-36 evaluation scale and the incidence of adverse reactions before and after treatment were compared between the two groups. Results The total effective rate of observation group was higher than that of control group, the difference was statistically significant (P <0.05). There were no significant differences in the number of lead involvement and epileptiform discharge between the two groups before treatment (P> 0.05). After treatment, the number of leads involved in the observation group and the epileptiform discharge were less than those in the control group, with significant difference P <0.05). The scores of physical function, general health, mental health, social function, mental function, vitality, physical and psychological quality of life, physical pain and emotional function score and total score in observation group were significantly higher than those in control group (P <0.05 ). The incidence of adverse reactions in observation group was lower than that in control group, the difference was statistically significant (P <0.05). Conclusion Xingnaojing auxiliary carbamazepine in the treatment of secondary epilepsy after stroke clinical efficacy, and high safety.